Johnson & Johnson
JNJ: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$431.00 | Qmlqg | Gnrbnlf |
J&J: Shockwave Acquisition Adds Fast-Growing Medical Devices
We are holding our $164 fair value estimate for J&J steady after its agreement to acquire Shockwave Medical for close to $13 billion. We believe the growth potential of Shockwave will help accelerate J&J’s medical devices segment by almost 50 basis points, largely in line with comments by high-level management. We expect close to $1 billion in sales from Shockwave products in 2025, followed by rapid growth in subsequent years.